Mr. Christopher brings more than 25 years of financial experience at a variety of publicly-traded life sciences companies to his role as InVivo’s Chief Financial Officer. Prior to joining InVivo, Mr. Christopher was the Chief Financial Officer of iCAD Inc., a Nasdaq-listed company with a focus on therapies and solutions for the early identification and treatment of cancer. Prior to iCAD Inc., Mr. Christopher was Chief Financial Officer and Chief Operating Officer of Caliber Imaging & Diagnostics, Inc., a medical technology company focused on cancer detection imaging solutions, with primary applications in dermatology. Before Caliber, Mr. Christopher held various positions of increasing responsibility at DUSA Pharmaceuticals, Inc., a Nasdaq-listed dermatology company focused on the treatment of precancerous skin lesions, where he ultimately served as Chief Financial Officer through its acquisition and integration into Sun Pharmaceuticals Industries Ltd. Mr. Christopher holds an M.S. in accounting from Suffolk University and a B.S. in finance from Bentley University.